2007

To help doctors give their patients the best possible care, ASCO asks its medical experts to develop recommendations for specific areas of cancer care. In 2004, ASCO published a clinical practice guideline about hormone therapy for advanced prostate cancer. This guideline was updated in 2007 to reflect developments in the treatment of advanced prostate cancer. This patient guide is based on ASCO's recommendations.

As you read this guide, please keep in mind that every person treated for cancer is different. These recommendations are not meant to replace your or your doctors' judgment. The final decisions you and your doctors make will be based on your individual circumstances.

Information in ASCO's patient education materials is not intended as medical advice or as a substitute for the treating doctor's own professional judgment; nor does it imply ASCO endorsement of any product, service, or company.

Advanced prostate cancer includes cancer that has spread, cancer that has returned after treatment, and cancer that continues to grow or spread despite treatment or while under surveillance. Because androgens (male sex hormones), such as testosterone, help the growth of prostate cancer, lowering the levels of androgens helps slow the growth of prostate cancer. Androgen deprivation therapy (ADT) is a hormone therapy that slows the growth of prostate cancer by lowering the levels of androgens or blocking the androgens from getting to the prostate cancer cell.

ADT includes the following treatments:

• Bilateral orchiectomy is the surgical removal of the testicles, the main source of testosterone production. Although this treatment is surgery, it is considered hormone therapy because it effectively removes most of the testosterone from the body. This treatment is also called surgical castration.
  
  
• Luteinizing hormone-releasing hormone (LHRH) agonists are drugs that lower the body's production of testosterone by stopping the testicles from making testosterone. These drugs are usually given as injections. This treatment is sometimes called medical castration.
  
  
• Anti-androgen drugs prevent the body from using testosterone. These drugs are in the form of a pill.
  
  
• Combined androgen blockade (CAB) is a treatment strategy to eliminate any remaining androgens in the body. It is a combination of an anti-androgen drug and either surgery or an LHRH agonist drug. Surgical or medical castration eliminates about 90% to 95% of the body's testosterone, and adding the anti-androgen eliminates the remaining 5% to 10% of the body's testosterone.

Some common side effects of hormone therapy may include:

• Psychological effects resulting from testicle removal
  
  
• Loss of sex drive
  
  
• Impotence (inability to have erections)
  
  
• Hot flashes
  
  
• Tiredness
  
  
• Mood changes
  
  
• Muscle shrinkage
  
  
• Enlarged and/or tender breasts
  
  
• Osteopenia and osteoporosis (loss of bone mass, which may result in a broken bone)
  
  
• Weight gain

Some uncommon or rare side effects of hormone therapy include:

• Rise in cholesterol
  
  
• Diabetes
  
  
• Heart disease
  
  
• Liver damage (rare)

Many of these side effects are treatable, and most side effects go away once treatment is finished, except those resulting from an orchiectomy, which are permanent. Men who have received an LHRH agonist drug for more than two years frequently experience persistent side effects for more than one year after the drug is discontinued, and some men never fully recover. In addition, recent research suggests that LHRH agonist therapy may also increase a man's risk of heart disease, heart attack, and death from cardiac arrest (sudden loss of heart function).

ASCO's recommendations for the use of hormone therapy for men with advanced prostate cancer that responds to treatment with anti-androgens are summarized below.

• For most men, the initial recommended treatment is the removal of testosterone through a bilateral orchiectomy or with an LHRH agonist drug. Each procedure has a specific set of physical and psychological side effects, and it is important to talk with your doctor to understand the risks and benefits of each treatment.
  
  
• An alternative to surgical or medical castration is a nonsteroidal anti-androgen drug. Bicalutamide (Casodex), flutamide (Eulexin) and nilutamide (Nilandron) are examples of anti-androgens. This treatment is as effective as a bilateral orchiectomy or an LHRH agonist drug, but it has different side effects (most notably, less effect on a man's sex drive).
  
  
• For men with prostate cancer that continues to grow and spread, CAB treatment lowers the risk of death by more than either method listed above. However, there may also be an increase in potentially serious side effects. It is important to talk with your doctor about risks and benefits of this treatment, especially in the context of your own health history.
  
  
• The timing of starting ADT should be discussed with your doctor. Research shows that starting treatment right away may not always be better. Most doctors recommend beginning treatment when a man shows symptoms of recurrent or progressive cancer. Men who are not treated right away should meet with their doctors every three to six months to monitor the cancer.

Intermittent hormone therapy is given for a specific time, stopped temporarily, and restarted again once the PSA hits a certain predetermined level. At this time, the use of intermittent hormone therapy is still considered experimental. Although a man's quality of life will likely be better during the "off therapy" periods (the time when the hormones are temporarily stopped), it is not known whether intermittent hormone therapy controls the cancer as long as continuous hormone therapy.

Hormone therapy for prostate cancer comes in several forms: surgical removal of the testicles, LHRH agonist drugs, anti-androgen drugs, and a combination of these treatments. Men with advanced prostate cancer should discuss with their doctors the risks and benefits of all the treatment options and when to begin treatment. This discussion should address the current state of the cancer (such as whether PSA levels are rising or steady and whether the cancer has spread to the bones), your health history, and other medical conditions, such as diabetes. You may also want to discuss any concerns you may have about how your sexual and physical functioning might be affected by hormone therapy. For some men, the side effects of prostate cancer treatment are a bigger risk to their health than the prostate cancer itself, so it is important to talk with your doctor about the long-term side effects of a particular treatment.

To learn more about hormone therapy for advanced prostate cancer, consider asking your doctor the following questions:

• What are my options for treatment?



• What are the possible side effects of these treatment options?



• How will treatment affect my sexual and emotional well-being?



• How will treatment affect my fertility?



• Which treatment do you recommend, given my health history?



• What type of follow-up care is necessary after treatment?



• Do I need to begin treatment right away?



• If my treatment is delayed, how will the cancer be monitored?



• Am I eligible for a clinical trial?

Read the entire clinical practice guideline published in the April 20, 2007 Journal of Clinical Oncology (JCO).

Cancer.Net Guide to Prostate Cancer

Cancer.Net (www.cancer.net) is the comprehensive, oncologist-approved cancer information website from ASCO. Visit Cancer.Net to find guides on more than 120 types of cancer and cancer-related syndromes, clinical trials information, coping resources, information on managing side effects, medical illustrations, cancer information in Spanish, the latest cancer news, and much more. For more information about ASCO’s patient information resources, call toll free 888-651-3038.

American Cancer Society
1599 Clifton Rd., NE
Atlanta, GA  30329-4251
Toll Free: 800-ACS-2345 (800-227-2345)
TTY: 866-288-4327
Phone: 404-320-3333
www.cancer.org

American Urological Association Foundation
1000 Corporate Blvd.
Linthicum, MD  21090
Toll Free: 866-746-4282
Phone: 410-689-3700
www.UrologyHealth.org

CancerCare
275 Seventh Ave.
New York, NY  10001
Toll Free: 800-813-HOPE (800-813-4673)
Phone: 212-712-8400
www.cancercare.org

National Cancer Institute
Public Inquiries Office
Building 31, Rm. 10A31
31 Center Dr., MSC 2580
Bethesda, MD  20892-2580
Toll Free: 800-4-CANCER (800-422-6237) TTY: 800-332-8615
Phone: 301-435-3848
www.cancer.gov

National Prostate Cancer Coalition
1154 15th St., NW
Washington, DC  20005
Toll Free: 888-245-9455
Phone: 202-463-9455
www.4npcc.org

Prostate Cancer Education Council
5299 DTC Blvd., Ste. 345
Greenwood Village, CO  80111
Toll Free: 866-477-6788
Phone: 303-316-4685
www.pcaw.com

Prostate Cancer Foundation
1250 Fourth St.
Santa Monica, CA  90401
Toll Free: 800-757-CURE (800-757-2873)
Phone: 310-570-4700
www.prostatecancerfoundation.org

The Prostate Net, Inc.
P.O. Box 2192
Secaucus, NJ  07096-2192
Toll Free: 888-4-PROSNET (888-477-6763)
www.prostate-online.org

Us TOO International, Inc.
Prostate Cancer Education and Support
5003 Fairview Ave.
Downers Grove, IL  60515
Toll Free: 800-80-USTOO (800-808-7866)
Phone: 630-795-1002
www.ustoo.org

The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians of all oncology subspecialties who care for people with cancer. ASCO's nearly 25,000 members from the United States and abroad set the standard for patient care and lead the efforts to discover more effective cancer treatments, increase funding for clinical and translational research, and, ultimately, improve cancer care for the estimated 10 million people diagnosed with cancer worldwide each year. ASCO publishes the Journal of Clinical Oncology (JCO), the preeminent, peer-reviewed, medical journal on clinical cancer research, and produces Cancer.Net (www.cancer.net), a comprehensive consumer website providing oncologist-vetted cancer information to help patients and families make informed health-care decisions.

American Society of Clinical Oncology
2318 Mill Road, Ste. 800
Alexandria, VA  22314
Phone: 571-483-1300

www.asco.org
www.cancer.net
www.jco.org
www.jopasco.org
www.ascofoundation.org

© 2007 American Society of Clinical Oncology. For permissions information, contact permissions@asco.org.